The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Volchkov V.A.

St. Petersburg State University;
St. Petersburg City Multi-field Hospital No. 2

Zhuravlev M.M.

St. Petersburg City Multi-field Hospital No. 2

Shakh B.N.

St. Petersburg State University;
St. Petersburg City Multi-field Hospital No. 2

Boyarkin A.A.

St. Petersburg State University;
St. Petersburg City Multi-field Hospital No. 2

Parallel extracorporeal circulation during endovascular interventions in cardiac surgery patients

Authors:

Volchkov V.A., Zhuravlev M.M., Shakh B.N., Boyarkin A.A.

More about the authors

Read: 3224 times


To cite this article:

Volchkov VA, Zhuravlev MM, Shakh BN, Boyarkin AA. Parallel extracorporeal circulation during endovascular interventions in cardiac surgery patients. Russian Journal of Anesthesiology and Reanimatology. 2022;(6):91‑98. (In Russ., In Engl.)
https://doi.org/10.17116/anaesthesiology202206191

Recommended articles:
Methemoglobinemia with symptoms of acute coro­nary syndrome. Russian Journal of Anesthesiology and Reanimatology. 2025;(1):101-108

Introduction

Multivessel coronary artery disease in non-ST elevation acute coronary syndrome (NSTE-ACS) occurs in more than 50% of patients [1, 2]. Indications for surgical or endovascular revascularization are often not established in some patients with NSTE-ACS due to high risk of intraoperative complications [3]. As a rule, these patients undergo therapy. Cardiac surgeons refuse coronary bypass surgery due to high perioperative risk (Euroscore II), and endovascular surgeons refrain from percutaneous coronary intervention (PCI) due to high SYNTAX score (Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery).

SYNTAX score facilitates optimal treatment selection by identifying patients with high risk of adverse events after PCI. This index also reflects prohibitive risk of unfavorable outcomes following difficult PCI. Therapeutic treatment of patients with NSTE-ACS and multivessel coronary artery disease who are denied revascularization is accompanied by high in-hospital mortality (about 28%) and poor quality of life [4].

Preliminary data on high-risk PCI under support of extracorporeal circulation in patients with NSTE-ACS and multivessel coronary artery disease who were denied conventional revascularization show encouraging clinical results. Case fatality rate/mortality rate within 12 months is 5.5–6.2% / 8.7–11% [5].

Modern extracorporeal support systems are quite diverse (intra-aortic balloon counterpulsation (IABP), Impella (2.5; 3.5; 5.0), TandemHeart, iVAC 2L). However, only parallel cardiopulmonary bypass maintains blood circulation and oxygenation [6, 7].

In our work, extracorporeal support was ensured by heart-lung machine. There are two options for its intraoperative application. The first option is complete artificial circulation characterized by complete replacement of cardiac output. The second option is partial replacement with effective intrinsic cardiac output (parallel CPB). In this case, perfusion rate is adjusted considering hemodynamic and metabolic needs. In this work, we used parallel CPB.

A 84-year-old patient B. (resident of St. Petersburg) was hospitalized with angina pectoris and shortness of breath when walking on a flat surface within 20–30 m. Symptoms disappeared at rest after 3–5 minutes. There was also feeling of lack air in horizontal position with relief in sitting position. After examination, we established the following diagnosis: coronary artery disease, NSTE-ACS, post-infarction cardiac sclerosis (previous myocardial infarction with recurrent infarction in December 2018); stage III hypertension with high risk of cardiovascular complication; severe degenerative aortic stenosis, moderate mitral insufficiency, mild aortic insufficiency; cerebrovascular disease, previous stroke, hypoxic-ischemic encephalopathy stage II; atherosclerosis of the aorta and cerebral arteries, lower limb arteries; previous angioplasty and stenting of the right coronary artery in December 2018. Complications: moderate pulmonary hypertension; chronic heart failure stage Iib class IV. Concomitant diseases: chronic pyelonephritis without exacerbation, gastroesophageal reflux disease, chronic gastritis, impaired glucose tolerance; previous surgery for basal cell carcinoma of the forehead skin (June 29, 2018); mild anemia; diffuse nodular toxic goiter, euthyroidism.

Echocardiography data: impaired contractility of the left ventricle (ejection fraction 28%), severe aortic stenosis (blood flow velocity 4.2 m/s, maximum pressure gradient 80 mm Hg, mean pressure gradient 44 mm Hg, orifice area 0.7 cm2), pulmonary artery pressure 46 mm Hg.

Coronary angiography revealed stenosis of the left main coronary artery 80%, proximal subocclusion of the left anterior descending artery with diffuse lesions of its walls, subocclusion of diagonal artery, middle third of circumflex artery, proximal stenosis 60% of obtuse marginal artery (Fig. 1).

Fig. 1. Coronarography. Stenosis of the left main coronary artery 80%, subocclusion and diffuse lesions of the proximal third of the left anterior descending artery, subocclusion of the first diagonal artery, subocclusion of the middle third of circumflex artery, proximal stenosis 60% of the obtuse marginal artery.

Determining treatment strategy, we considered age (84 years), coronary lesion (severe multivessel coronary artery disease with involvement of the left main coronary artery), concomitant diseases and complications (previous myocardial infarction within 90 days before the present surgery, post-infarction cardiac sclerosis), RCA stenting in December 2018, severe aortic stenosis (blood flow velocity 4.2 m/s, maximum pressure gradient 80 mm Hg, mean pressure gradient 44 mm Hg, orifice area 0.7 cm2) with reduced ejection fraction (28%), moderate mitral insufficiency, mild aortic insufficiency, previous stroke in August 2018, moderate pulmonary hypertension, chronic heart failure class IV, impaired glucose tolerance, mild anemia, decreased glomerular filtration rate (50 ml/min/1.73 m2). Both endovascular intervention (SYNTAX score 33, PTCA score 16) and open cardiac surgery were rejected due to high risk of unfavorable outcomes (Euroscore II 40.76%).

Considering high mortality following drug therapy and vital indications for myocardial revascularization, we scheduled stenting of the left main coronary artery, LAD, circumflex artery, balloon valvuloplasty of the aortic valve under general anesthesia and parallel CPB. ASA grade 4 was determined by severe systemic disease, permanent threat to life and high risk of sudden cardiac death.

We established perioperative management considering objective status, underlying and concomitant diseases, diagnostic data and some other features. First, influence of preload on stroke volume is limited by severe atherosclerosis, and overload could lead to dilatation of the left chambers, left atrium, left ventricle and mitral annulus, as well as aggravation of mitral regurgitation. With this in mind, we planned to replenish intravascular volume in accordance with the target hemodynamic parameters and clinical response to volemic load. The second feature is the need to maintain heart rate within a narrow range (60–80 beats/min), since high rate is accompanied by decrease in coronary perfusion, and low rate is associated with limitation of cardiac output in a patient with a fixed stroke volume. It was important to maintain sinus rhythm for ensuring sufficient systolic ejection time through the stenotic aortic valve.

When choosing the method of anesthesia, we considered the following circumstances. Cardiac output cannot be increased in response to decrease in heart rate in patients with severe aortic stenosis. These ones require alpha-adrenergic receptor agonists to prevent blood pressure decrease and potential sudden death. This is because LV afterload is primarily determined by aortic stenosis, so this component remains constant. Blood pressure decrease is followed by only mild decrease in LV afterload. Thus, arterial hypotension can quickly develop in response to injection of most anesthetics. In this case, hypertrophied myocardium is at high risk of ischemia, since coronary blood flow depends on systemic diastolic pressure. Moreover, most patients with severe mitral regurgitation develop pulmonary hypertension due to increased left atrial pressure and pulmonary resistance. Hypercapnia and nitrous oxide sedation should be avoided in patients with elevated pulmonary vascular resistance due to the risk of reactive pulmonary vasoconstriction. Therefore, we used total intravenous anesthesia. Anesthetic strategy had certain features (Fig. 2).

Fig. 2 Anesthetic card.

Mild oral premedication with hydroxyzine hydrochloride 25 mg the day before provided peace of mind for the patient and prevented tachycardia. Upon admission to the operating theatre, the patient had normal heart rate and mild arterial hypotension (BP 90/60 mm Hg) without clinical signs of hypoperfusion (SHOCK stage B) [8]. However, analyzing oxygen delivery (DO2) and consumption (VO2), we found oxygen debt (DO2/VO2 ratio = 490 ml/min : 190 ml/min = 2.5 : 1.0, norm 5 : 1). The extraction index was 39% (norm 20–25%) that also indicated insufficient tissue perfusion and confirmed the need for CPB. An experienced surgeon and perfusionist were ready for emergency CPB in case of severe hemodynamic disorders.

Under aseptic conditions and local anesthesia, an introducer was inserted into the right femoral artery to measure blood pressure. Invasive BP monitoring was necessary for immediate recognition and correction of hemodynamic changes, as well as serial sampling of arterial blood gases.

Preoperative blood test: WBC = 5.06×109 /L; Neu = 3.4×109 /l; Hb = 112 g/l; Ht = 35.1%; RBC = 3.62×1012 /L; PLT = 190×109 /L; AST = 36 U/l; ALT = 24 U/l; creatinine = 86 µmol/l; total bilirubin = 19.5 µmol/l; potassium = 4.0 mmol/l; sodium = 138 mmol/l; glucose = 6.24 mmol/l; activated partial thromboplastin time = 33.9 s; INR = 1.06; prothrombin = 95%; prothrombin time = 11.8 s. Arterial blood gases: pH = 7.249; pCO2 = 45.7 mm Hg; pO2 = 53.6 mm Hg; BE = -7; HCO3¯ = 18.5 mmol/l; SpO2 = 82.7%.

Induction of anesthesia was followed by intubation and mechanical ventilation. We injected propofol (2 µg/ml) and fentanyl (5 µg/kg/hour) to maintain anesthesia. Deep muscle relaxation was provided by bolus intravenous pipecuronium bromide 2 mg every 40 min.

Mechanical ventilation was performed in CMV mode (Vte = 500 ml, f = 12/min, MV = 6.0 l/min, PEEP = 5 cm H2O, Preak = 19 cm H2O, Pplato = 12, I:E = 1:2, FiO2 = 50%). Parameters were corrected considering arterial and venous blood gases. Hemodynamic support during anesthesia was maintained by intravenous infusion of noradrenaline (0.03–0.06 μg/kg/min). Anemia following intraoperative blood loss and hemodilution was compensated by RBC and fresh frozen plasma transfusion.

Central venous catheter was inserted through internal jugular vein under ultrasound guidance, and electrode for temporary pacing was passed to the apex of the right ventricle. Left femoral artery and vein were used to establish CPB.

Considering short-term surgery and cost feasibility, we preferred on-pump surgery. We established perfusion rate at 4.9 l/min considering growth and weight of the patient.

Priming solution for heart-lung machine included isotonic Sterofundin 500 ml, sodium chloride 0.9% 500 ml, sodium bicarbonate 3% 150 ml, Mannitol 15% 400 ml, furosemide 20 mg, heparin 5000 IU, potassium chloride 10% 10 ml. The total filling volume was 1550 ml.

Auxiliary circulation was performed under mild hypothermia (35°C) with standard hemodilution (Ht 25-28%) and perfusion rate of 36–60% of the calculated one (1.8–3.0 l/min) to maintain target systolic blood pressure 60-70 mm Hg. Mean BP during CPB was 50–80 mm Hg, central venous pressure 0-5 mm Hg, SpO2 95-100%. Unfractionated heparin 300 U/kg was injected before perfusion (total dose 23,000 IU). After that, we controlled ACT (target value > 400 s) to determine the need for additional dose of heparin (Table 1, 2).

Table 1. Intraoperative parameters of cardiopulmonary bypass

Time

Perfusion rate, l/min

BP, mm Hg

Central venous pressure, cm H2O

FiO2

ACT, c

11:48

3.0

90/50

0

0.7

702

12:34

2.8

100/60

+5

0.7

453

13:35

2.0

95/60

+2

0.7

470

14:31

1.8

100/60

+1

0.7

412

Table 2. Intraoperative arterial and venous blood gases

Time

pH

pO2, mm Hg.

pCO2, mm Hg

BE

SB

K+, mmol/l

Ht, %

Arterial blood gases

11:48

7.44

359

29

–3.5

21.5

4.2

26

12:34

7.48

378

24

–4

21

4.2

24

13:35

7.51

372

28.5

–4

18

4.3

25

14:31

7.52

368

31

–6

19

4.8

25

Venous blood gases

11:48

7.42

56.8

31

–3.8

21

4.2

26

12:34

7.43

55

29

–4

21

4.2

24

13:35

7.41

46

29.5

–4

19

4.3

25

14:31

7.37

47

30

–6

19

4.8

25

At the first surgical stage under CPB, we implanted 2 stents in the left anterior descending artery, 1 stent in circumflex artery and 1 stent in the left main coronary artery. Control angiography (TIMI III) is presented in Fig. 3.

Fig. 3. Balloon angioplasty of the left anterior descending artery with implantation of 2 stents.

Balloon angioplasty of the circumflex artery with implantation of 1 stent. Stenting of the left main coronary artery with 1 stent and post-dilatation with a balloon. TIMI III.

Balloon valvuloplasty of the aortic valve was performed under parallel perfusion and RV stimulation (180/min) (Fig. 4).

Fig. 4. Right ventricular pacing by external pacemaker (180 per a minune) with simultaneous balloon aortic valve valvuloplasty under cardiopulmonary bypass.

After stabilization of blood pressure, the patient was transferred to normothermic perfusion. Then, we gradually decreased extracorporeal support considering spontaneous cardiac output, blood pressure, heart rate and signs of hypoperfusion (diuresis, peripheral blood flow, laboratory data). Arterial blood gases early after CPB (perfusion rate 1 l/min): pH = 7.326; pCO2 = 38 mm Hg; pO2 = 156 mm Hg; BE = -6.3; HCO3¯= 19.1 mmol/l; SpO2 = 99.2%. Invasive monitoring demonstrated stable BP (100/60 mm Hg) under alpha-adrenomimetic support with norepinephrine 0.06 μg/kg/min. There were no ultrasound signs of bleeding into pericardial cavity. CPB was stopped. Heparin was neutralized with protamine sulfate 230 mg. CPB time was 185 min, fluid balance during perfusion period — 950 ml (+).

Acute decrease in pressure gradient on the aortic valve was followed by immediate reduction of LV end-diastolic pressure with simultaneous increase in stroke volume. Left atrial and pulmonary artery pressure decreased. Myocardial function improved rapidly, although hypertrophied ventricle still required preload and afterload control.

In early postoperative period, we observed arterial hypotension and the need for vasopressor support with norepinephrine. Doses decreased from 0.10 to 0.05 μg/kg/min. Elevation of troponin I with peak values after 3-4 days and no ECG abnormalities or impaired LV contractility was due to surgical intervention. Agitation, disorientation in space and time, as well as no adequate verbal contact (RASS score 3) were observed on the first day after surgery. Sedation with propofol 100 mg/h under respiratory support was continued for a day. The patient was weaned from ventilator using the RSBI protocol in 2 postoperative days after assessing the consciousness and severity of agitation (RASS score 0-1).

Blood test in ICU: WBC = 13.9×109 /L; Neu = 12.9×109 /L; Hb = 82 g/l; Ht = 23.1%; RBC = 2.66×1012 /L; PLT = 122×109 /L; AST = 36 U/l; ALT = 20 U/l; creatinine = 119 µmol/l; total bilirubin = 25 µmol/l; potassium = 4.1 mmol/l; sodium = 145 mmol/l; glucose = 9.0 mmol/l; troponin I = 946.8 pg/ml; APTT = 39.6 s; INR = 1.35; prothrombin = 66%; prothrombin time = 15.1 s. Arterial blood gases: pH = 7.35; pCO2 = 33 mm Hg; pO2 = 128 mm Hg; BE = -6.7; HCO3¯ = 18.2 mmol/l; SpO2 = 99%; sodium = 138 mmol/l; potassium = 3.9 mmol/l; calcium = 1.07 mmol / l.

The main postoperative problems were anemia, hemodynamic instability and transient agitation with RASS score +3. Intensive care included transfusion of 3 doses of packed RBC and 1 dose of fresh frozen plasma (Hb 95 g/l and Ht 28.3% at discharge). Hemodynamic support was canceled after 4 postoperative days. We constantly assessed consciousness throughout the entire ICU-stay. There was a wave-like changes in consciousness (RASS score from 0 to +3). Measures were taken to organize circadian rhythm (sedation only at night). Visits of relatives and constant contact of patient with staff for medical and domestic issues were essential. Consciousness was normalized after 6-day intensive care. The patient was sociable, friendly, fully oriented in space and own personality, as well as ready to cooperate with the staff. Clinical state improved under therapy. After 7 postoperative days, the patient was transferred to the specialized department. Angina pectoris did not recur, and circulatory insufficiency regressed. The patient was discharged in 21 days after surgery.

LV ejection fraction increased from 28 to 48%, LV contractility increased, LV end-diastolic volume decreased from 210 to 110 ml. Mean pressure gradient on the aortic valve decreased from 44 to 23 mm Hg. Pulmonary artery pressure decreased from 46 to 29 mm Hg. Moreover, blood flow velocity through the aortic valve decreased from 4.2 to 3.3 m/s, maximum pressure gradient decreased from 80 to 47 mm Hg, mean gradient decreased from 44 to 33 mm Hg. Aortic valve orifice area increased from 0.7 to 2.3 cm2.

A month later, the second stage of surgical treatment was performed (transcatheter aortic valve implantation).

Discussion

Cardiac patients with multivessel coronary artery disease, severe comorbidities and high risk of perioperative mortality have poor adaptive cardiovascular capacity. Surgery may be followed by abnormal processes with decrease in cardiac output, progressive ischemia, cardiogenic shock or malignant ventricular arrhythmia. In some cases, cardiogenic shock develops before surgery.

Mechanical circulatory support (in this case, parallel cardiopulmonary bypass) effectively replaces heart function in case of cardiac arrest or life-threatening arrhythmia. Oxygenator may be required in patients with respiratory dysfunction. The disadvantage of this method is increase in afterload that may be critical in patients with reduced LV contractility, for example, in cardiogenic shock. This disadvantage can be corrected by optimizing circulatory support with adjusting perfusion rate. More invasive technique is puncture of atrial septum for left heart decompression.

There are literature data on the positive impact of extracorporeal circulation providing cardiopulmonary support in patients with refractory cardiac arrest and cardiogenic shock.

Radsel P. et al. [9] analyzed 3 scenarios (extracorporeal support before intervention, during and after surgery when hemodynamic instability progresses). The authors concluded that emergency veno-arterial extracorporeal support provides immediate hemodynamic stabilization and saves time for PCI in patients with refractory cardiac arrest undergoing chest compressions and in patients with cardiogenic shock refractory to standard therapy. The authors report 83% success rate for PCI and describe successful on-pump transcatheter aortic valve implantation in 4 patients with low LV ejection fraction. Successful radiofrequency ablation followed by pacemaker implantation under extracorporeal support was described. Overall in-hospital survival was 44%. Takayama H. et al. [10] reported survival rate of 49% in patients with cardiogenic shock undergoing treatment under extracorporeal support. However, the authors note that 50% of survivors require heart transplantation in the future.

Vereshchagin I.E. et al. [11] compared the results of high-risk PCI in patients with acute coronary syndrome supported by extracorporeal membrane oxygenation and intra-aortic balloon counterpulsation. The study recruited 34 patients including 18 ones after PCI under extracorporeal membrane oxygenation and 16 patients after PCI under intra-aortic balloon counterpulsation. Long-term (12 months) results showed the advantage of intraoperative ECMO.

To date, there are no clear recommendations that would definitely answer the question of the need for extracorporeal support in ACS. Our clinical case demonstrates the possibility of parallel CPB in the treatment of high-risk patients with ACS scheduled for PCI.

Conclusion

This clinical observation confirms that CPB-assisted endovascular interventions may be effective in patients with severe coronary artery disease and high risk of mortality. The main features of perioperative intensive care were the need for multidirectional correction of intravascular volume at different stages of surgery and cardiopulmonary bypass in accordance with the target hemodynamic parameters and clinical response, timely correction of anemia and blood loss, correction of ventilation parameters under control of blood gases, early intraoperative use of alpha-agonists, careful monitoring of blood clotting parameters and surgical hemostasis under total heparinization during cardiopulmonary bypass and after heparin reversal, careful cardiorespiratory monitoring at all stages of intensive care.

Author contribution:

Concept and design of the study — Volchkov V.A., Zhuravlev M.M., Shakh B.N., Boyarkin A.A.

Collection and analysis of data — Zhuravlev M.M.

Writing the text — Volchkov V.A., Zhuravlev M.M., Shakh B.N., Boyarkin A.A.

Editing — Volchkov V.A., Zhuravlev M.M., Shakh B.N.

The authors declare no conflicts of interest.

References:

  1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119-177.  https://doi.org/10.1093/eurheartj/ehx393
  2. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2021;42(14):1289-1367. https://doi.org/10.1093/eurheartj/ehaa575
  3. Barbarash LS, Ganyukov VI, Popov VA, Tarasov RS, Torgunakov SA, Kochergin NA, Barbarash OL. Hospital results of treatment of acute coronary syndrome without ST-segment elevation in multivessel coronary artery disease, depending on the method and strategies of revascularization. Kardiologicheskij vestnik. 2013;8(2-20):17-23. (In Russ.).
  4. Ganyukov VI, Tarasov RS, Neverova YuN, Kochergin NA, Barbarash OL. Long-term results of different approaches to revascularization in non-ST-segment elevation acute coronary syndrome and multiple coronary atherosclerosis. Terapevticheskij arkhiv. 2017;89(4):29-34. (In Russ.). https://doi.org/10.17116/terarkh201789429-34
  5. Kornelyuk RA, Vereshchagin IE, Shukevich DL, Ganyukov VI. Mechanical circulatory support in high-risk percutaneous coronary intervention. Kompleksnye problemy serdechno-sosudistykh zabolevanij. 2018;7(4S):54-65. (In Russ.). https://doi.org/10.17802/2306-1278-2018-7-4S-54-65
  6. Kar S. Percutaneous Mechanical Circulatory Support Devices for High-Risk Percutaneous Coronary Intervention. Current Cardiology Reports. 2018;20(1):2.  https://doi.org/10.1007/s11886-018-0946-2
  7. Bazylev VV, Rosseikin EV, Evdokimov ME, Pantyukhina MA, Kokashkin MV, Kobzev EE. Extracorporeal support using a standard oxygenator as a component of cardiopulmonary resuscitation in hospital cardiac arrest in patients with cardiac surgery. Anesteziologiya i Reanimatologiya. 2018;5:53-59. (In Russ.). https://doi.org/10.17116/anaesthesiology201805153
  8. Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, Hollenberg SM, Kapur NK, O’Neill W, Ornato JP, Stelling K, Thiele H, van Diepen S, Naidu SS. SCAI clinical expert consensus statement on the classification of cardiogenic shock. This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheterization and Cardiovascular Interventions. 2019;94(1):29-37.  https://doi.org/10.1002/ccd.28329
  9. Radsel P, Goslar T, Bunc M, Ksela J, Gorjup V, Noc M. Emergency veno-arterial extracorporeal membrane 3 oxygenation (VA ECMO)-supported percutaneous 4 interventions in refractory cardiac arrest and 5 profound cardiogenic shock. Resuscitation. 2021;160:150-157.  https://doi.org/10.1016/j.resuscitation.2020.11.028
  10. Takayama H, Truby L, Koekort M, Uriel N, Colombo P, Mancini DM, Jorde UP, Naka Y. Clinical outcome of mechanical circulatory support for refractory cardiogenic shock in the current era. The Journal of Heart and Lung Transplantation. 2013;32(1):106-111.  https://doi.org/10.1016/j.healun.2012.10.005
  11. Vereshchagin IE, Ganyukov VI, Kochergin NA, Kornelyuk RA, Barbarash OL. Results of percutaneous intervention in acute coronary syndrome depending on the type of mechanical hemodynamic circulatory support. Patologiya krovoobrashcheniya i kardiokhirurgiya. 2019;23(1 Suppl 1): 34-43. (In Russ.). https://doi.org/10.21688/1681-3472-2019-1S-S34-S43
  • Yakhno NN, Shtulman DR. Bolezni nervnoj sistemy. V 2 t. (4-e izdanie). M.: Meditsina; 2005. (In Russ.).
  • Tugasworo D, Kurnianto A, Retnaningsih, Andhitara Y, Ardhini R, Budiman J. The relationship between myasthenia gravis and COVID-19: A systematic review. Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):83.  https://doi.org/10.1186/s41983-022-00516-3
  • Heliopoulos I, Patlakas G, Vadikolias K, et al. Maximal voluntary ventilation in myasthenia gravis. Muscle Nerve. 2003;27(6):715-719.  https://doi.org/10.1002/mus.10378
  • Galassi G, Marchioni A. Myasthenia gravis at the crossroad of COVID-19: focus on immunological and respiratory interplay. Acta Neurol Belg. 2021; 121(3):633-642.  https://doi.org/10.1007/s13760-021-01612-6
  • Roper J, Fleming ME, Long B, Koyfman A. Myasthenia Gravis and Crisis: Evaluation and Management in the Emergency Department. J Emerg Med. 2017;53(6):843-853.  https://doi.org/10.1016/j.jemermed.2017.06.009
  • Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. The pathophysiology of ‘happy’ hypoxemia in COVID-19. Respir Res. 2020;21(1):198. Published 2020 July 28.  https://doi.org/10.1186/s12931-020-01462-5
  • Tobin MJ, Laghi F, Jubran A. Why COVID-19 Silent Hypoxemia Is Baffling to Physicians. Am J Respir Crit Care Med. 2020;202(3):356-360.  https://doi.org/10.1164/rccm.202006-2157CP
  • Neumann B, Angstwurm K, Mergenthaler P, et al. Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases [published correction appears in Neurology. 2020 Apr 21;94(16):724. Schneider, Haucke [corrected to Schneider, Hauke]]. Neurology. 2020;94(3):299-313.  https://doi.org/10.1212/WNL.0000000000008688
  • International MG/COVID-19 Working Group, Jacob S, Muppidi S, et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;412:116803. https://doi.org/10.1016/j.jns.2020.116803
  • Hoang P, Hurtubise B, Muppidi S. Clinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection. Neurology. 2020;95(18):840-843.  https://doi.org/10.1212/WNL.0000000000010651
  • Heiman-Patterson T, Martino C, Rosenberg H, Fletcher J, Tahmoush A. Malignant hyperthermia in myotonia congenita. Neurology. 1988;38(5):810-812.  https://doi.org/10.1212/wnl.38.5.810
  • Arcas M, Sánchez-Ortega JL, García-Muñoz M, Alonso B, del Yelmo F, López-Rodríguez F. Anestesia para cesárea en un caso de miotonía congénita [Anesthesia for cesarean delivery in a case of myotonia congenita]. Rev Esp Anestesiol Reanim. 1996;43(4):147-149. (In Spanish).
  • Bisinotto FM, Fabri DC, Calçado MS, Perfeito PB, Tostes LV, Sousa GD. Anesthesia for videolaparoscopic cholecystectomy in a patient with Steinert disease. Case report and review of the literature. Rev Bras Anestesiol. 2010;60(2):181-110.  https://doi.org/10.1016/s0034-7094(10)70024-6
  • Haeseler G, Störmer M, Bufler J, et al. Propofol blocks human skeletal muscle sodium channels in a voltage-dependent manner. Anesth Analg. 2001;92(5):1192-1198. https://doi.org/10.1097/00000539-200105000-00021
  • Haeseler G, Störmer M, Mohammadi B, et al. The anesthetic propofol modulates gating in paramyotonia congenita mutant muscle sodium channels. Muscle Nerve. 2001;24(6):736-743.  https://doi.org/10.1002/mus.1064
  • Weller JF, Elliott RA, Pronovost PJ. Spinal anesthesia for a patient with familial hyperkalemic periodic paralysis. Anesthesiology. 2002;97(1):259-260.  https://doi.org/10.1097/00000542-200207000-00033
  • Allison KR. Muscular dystrophy versus mitochondrial myopathy: the dilemma of the undiagnosed hypotonic child. Paediatr Anaesth. 2007;17(1):1-6.  https://doi.org/10.1111/j.1460-9592.2006.02106.x
  • Flewellen EH, Bodensteiner JB: Anesthetic experience in a patient with hyperkalemic periodic paralysis. Anesth Rev. 1980;7:44. 
  • Viscomi CM, Ptacek LJ, Dudley D. Anesthetic management of familial hypokalemic periodic paralysis during parturition. Anesth Analg. 1999;88(5):1081-1082. https://doi.org/10.1097/00000539-199905000-00021
  • Siler JN, Discavage WJ. Anesthetic management of hypokalemic periodic paralysis. Anesthesiology. 1975;43(4):489-490.  https://doi.org/10.1097/00000542-197510000-00018
  • Löfgren A, Hahn RG. Hypokalemia from intercostal nerve block. Reg Anesth. 1994;19(4):247-254. 
  • Zisfein J, Sivak M, Aron AM, Bender AN. Isaacs’ syndrome with muscle hypertrophy reversed by phenytoin therapy. Arch Neurol. 1983;40(4):241-242.  https://doi.org/10.1001/archneur.1983.04050040071012
  • Van den Berg JS, van Engelen BG, Boerman RH, de Baets MH. Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. J Neurol. 1999;246(7):623-625.  https://doi.org/10.1007/s004150050419
  • Ashizawa T, Butler IJ, Harati Y, Roongta SM. A dominantly inherited syndrome with continuous motor neuron discharges. Ann Neurol. 1983;13(3):285-290.  https://doi.org/10.1002/ana.410130310
  • Hosokawa S, Shinoda H, Sakai T, Kato M, Kuroiwa Y. Electrophysiological study on limb myokymia in three women. J Neurol Neurosurg Psychiatry. 1987;50(7):877-881.  https://doi.org/10.1136/jnnp.50.7.877
  • Morgan PJ. Peripartum management of a patient with Isaacs’ syndrome. Can J Anaesth. 1997;44(11):1174-1177. https://doi.org/10.1007/BF03013340
  • McNicol ED, Tzortzopoulou A, Cepeda MS, Francia MB, Farhat T, Schumann R. Single-dose intravenous paracetamol or propacetamol for prevention or treatment of postoperative pain: a systematic review and meta-analysis. Br J Anaesth. 2011;106(6):764-775.  https://doi.org/10.1093/bja/aer107
  • Birnkrant DJ, Panitch HB, Benditt JO, et al. American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest. 2007;132(6):1977-1986. https://doi.org/10.1378/chest.07-0458
  • Maund E, McDaid C, Rice S, Wright K, Jenkins B, Woolacott N. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: A systematic review. Br J Anaesth. 2011;106(3):292-297.  https://doi.org/10.1093/bja/aeq406
  • Fowler SJ, Symons J, Sabato S, Myles PS. Epidural analgesia compared with peripheral nerve blockade after major knee surgery: A systematic review and meta-analysis of randomized trials. Br J Anaesth. 2008;100(2):154-164.  https://doi.org/10.1093/bja/aem373
  • Walker KJ, McGrattan K, Aas-Eng K, Smith AF. Ultrasound guidance for peripheral nerve blockade. Cochrane Database Syst Rev. 2009;(4):CD006459. Published 2009 Oct 7.  https://doi.org/10.1002/14651858.CD006459.pub2
  • Niranjan V, Bach JR. Noninvasive management of pediatric neuromuscular ventilatory failure. Crit Care Med. 1998;26(12):2061-2065. https://doi.org/10.1097/00003246-199812000-00042
  • Ruscic KJ, Grabitz SD, Rudolph MI, Eikermann M. Prevention of respiratory complications of the surgical patient: actionable plan for continued process improvement. Curr Opin Anaesthesiol. 2017;30(3):399-408.  https://doi.org/10.1097/ACO.0000000000000465
  • Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027-1049. https://doi.org/10.1177/0883073807305788
  • Almenrader N, Patel D. Spinal fusion surgery in children with non-idiopathic scoliosis: is there a need for routine postoperative ventilation? Br J Anaesth. 2006;97(6):851-857.  https://doi.org/10.1093/bja/ael273
  • Marchant WA, Fox R. Postoperative use of a cough-assist device in avoiding prolonged intubation. Br J Anaesth. 2002;89(4):644-647.  https://doi.org/10.1093/bja/aef227
  • Lebedinskii KM, Triadsky AA, Obolensky SV. Malignant hyperthermia: a pharmacogenetic caused by acute massive rhabdomyolysis. Anesteziologiya i Reanimatologiya. 2008;4:66-70. (In Russ.).
  • Wang CH, Bonnemann CG, Rutkowski A, et al. Consensus statement on standard of care for congenital muscular dystrophies. J Child Neurol. 2010;25(12):1559-1581. https://doi.org/10.1177/0883073810381924
  • Bach JR, Gonçalves MR, Hamdani I, Winck JC. Extubation of patients with neuromuscular weakness: A new management paradigm. Chest. 2010;137(5): 1033-1039. https://doi.org/10.1378/chest.09-2144
  • Miranda Rocha AR, Martinez BP, Maldaner da Silva VZ, Forgiarini Junior LA. Early mobilization: Why, what for and how? Med Intensiva. 2017;41(7):429-436.  https://doi.org/10.1016/j.medin.2016.10.003
  • Belkin AA, Alasheev AM, Belkin VA, et al. Rehabilitation in the intensive care unit (RehabICU). Clinical practice recommendations of the national Union of Physical and Rehabilitation Medicine Specialists of Russia and of the national Federation of Anesthesiologists and Reanimatologists. Russian Federation of anesthesiologists and reanimatologists guidelines. Annals of Critical Care. 2022;2:7-40. (In Russ). https://doi.org/10.21320/1818-474X-2022-2-7-40
  • Shousha AA, Sanfilippo M, Sabba A, Pinchera P. Sugammadex and reversal of neuromuscular block in adult patient with duchenne muscular dystrophy. Case Rep Anesthesiol. 2014;2014:680568. https://doi.org/10.1155/2014/680568
  • Shimauchi T, Yamaura K, Sugibe S, Hoka S. Usefulness of sugammadex in a patient with Becker muscular dystrophy and dilated cardiomyopathy. Acta Anaesthesiol Taiwan. 2014;52(3):146-148.  https://doi.org/10.1016/j.aat.2014.02.005
  • De Boer HD, Van Egmond J, Driessen JJ, Booij LHJD. Sugammadex in patients with myasthenia gravis. Anaesthesia. 2010;65(6):653.  https://doi.org/10.1111/j.1365-2044.2010.06360.x
  • Jakubiak J, Gaszyński T, Gaszyński W. Neuromuscular block reversal with sugammadex in a morbidly obese patient with myasthenia gravis. Anaesthesiol Intensive Ther. 2012;44(1):28-30. 
  • Sungur Ulke Z, Yavru A, Camci E, Ozkan B, Toker A, Senturk M. Rocuronium and sugammadex in patients with myasthenia gravis undergoing thymectomy. Acta Anaesthesiol Scand. 2013;57(6):745-748.  https://doi.org/10.1111/aas.12123
  • Vymazal T, Krecmerova M, Bicek V, Lischke R. Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery — a series of 117 cases. Ther Clin Risk Manag. 2015;11:1593-1596. Published 2015 Oct 15.  https://doi.org/10.2147/TCRM.S93009
  • Sungur Z, Sentürk M. Anaesthesia for thymectomy in adult and juvenile myasthenic patients. Curr Opin Anaesthesiol. 2016;29(1):14-19.  https://doi.org/10.1097/ACO.0000000000000272
  • Ortiz-Gómez JR, Palacio-Abizanda FJ, Fornet-Ruiz I. Failure of sugammadex to reverse rocuronium-induced neuromuscular blockade: A case report. Eur J Anaesthesiol. 2014;31(12):708-709.  https://doi.org/10.1097/EJA.0000000000000082
  • Email Confirmation

    An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

    Email Confirmation

    We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.